These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 15035849)

  • 1. Inhibition by interleukin-18 of the growth of Dunn osteosarcoma cells.
    Okamoto T; Yamada N; Tsujimura T; Sugihara A; Nishizawa Y; Ueda H; Kashiwamura S; Tsutsui H; Futani H; Maruo S; Okamura H; Terada N
    J Interferon Cytokine Res; 2004 Mar; 24(3):161-7. PubMed ID: 15035849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively.
    Hashimoto W; Osaki T; Okamura H; Robbins PD; Kurimoto M; Nagata S; Lotze MT; Tahara H
    J Immunol; 1999 Jul; 163(2):583-9. PubMed ID: 10395644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FR901228 induces tumor regression associated with induction of Fas ligand and activation of Fas signaling in human osteosarcoma cells.
    Imai T; Adachi S; Nishijo K; Ohgushi M; Okada M; Yasumi T; Watanabe K; Nishikomori R; Nakayama T; Yonehara S; Toguchida J; Nakahata T
    Oncogene; 2003 Dec; 22(58):9231-42. PubMed ID: 14647441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-2 induces Fas ligand/Fas (CD95L/CD95) cytotoxicity in CD8+ and CD4+ T lymphocyte clones.
    Esser MT; Dinglasan RD; Krishnamurthy B; Gullo CA; Graham MB; Braciale VL
    J Immunol; 1997 Jun; 158(12):5612-8. PubMed ID: 9190908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin (IL)-12 and IL-12 gene transfer up-regulate Fas expression in human osteosarcoma and breast cancer cells.
    Lafleur EA; Jia SF; Worth LL; Zhou Z; Owen-Schaub LB; Kleinerman ES
    Cancer Res; 2001 May; 61(10):4066-71. PubMed ID: 11358827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intranasal interleukin-12 gene therapy enhanced the activity of ifosfamide against osteosarcoma lung metastases.
    Duan X; Jia SF; Koshkina N; Kleinerman ES
    Cancer; 2006 Mar; 106(6):1382-8. PubMed ID: 16453328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumour activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12.
    Homma S; Komita H; Sagawa Y; Ohno T; Toda G
    Immunology; 2005 Aug; 115(4):451-61. PubMed ID: 16011514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence for the involvement of Fas ligand and perforin in the induction of vascular leak syndrome.
    Rafi AQ; Zeytun A; Bradley MJ; Sponenberg DP; Grayson RL; Nagarkatti M; Nagarkatti PS
    J Immunol; 1998 Sep; 161(6):3077-86. PubMed ID: 9743374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of antitumor immunity with Fas/APO-1 ligand (CD95L)-transfected neuroblastoma neuro-2a cells.
    Shimizu M; Fontana A; Takeda Y; Yagita H; Yoshimoto T; Matsuzawa A
    J Immunol; 1999 Jun; 162(12):7350-7. PubMed ID: 10358186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Augmentation of in vitro interleukin 10 production after in vivo administration of interleukin 18 is activated macrophage-dependent and is probably not involved in the antitumor effects of interleukin 18.
    Micallef MJ; Tanimoto T; Kohno K; Ikeda M; Ikegami H; Kurimoto M
    Anticancer Res; 1998; 18(6A):4267-74. PubMed ID: 9891477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of tumour metastasis in a murine osteosarcoma model with anti-CD25 monoclonal antibody treatment.
    Kozawa E; Sugiura H; Wasa J; Kohyama K; Yamada K; Nishioka A; Nishida Y; Ishiguro N; Taguchi O
    Anticancer Res; 2010 Dec; 30(12):5019-22. PubMed ID: 21187484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of antitumor immunity by combining anti-cytotoxic T lymphocyte antigen-4 antibodies and cryotreated tumor lysate-pulsed dendritic cells in murine osteosarcoma.
    Kawano M; Itonaga I; Iwasaki T; Tsumura H
    Oncol Rep; 2013 Mar; 29(3):1001-6. PubMed ID: 23291864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways.
    Zimmerman Z; Shatry A; Deyev V; Podack E; Mammolenti M; Blazar BR; Yagita H; Levy RB
    Biol Blood Marrow Transplant; 2005 Aug; 11(8):576-86. PubMed ID: 16041307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-18 up-regulates perforin-mediated NK activity without increasing perforin messenger RNA expression by binding to constitutively expressed IL-18 receptor.
    Hyodo Y; Matsui K; Hayashi N; Tsutsui H; Kashiwamura S; Yamauchi H; Hiroishi K; Takeda K; Tagawa Y; Iwakura Y; Kayagaki N; Kurimoto M; Okamura H; Hada T; Yagita H; Akira S; Nakanishi K; Higashino K
    J Immunol; 1999 Feb; 162(3):1662-8. PubMed ID: 9973427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasmodium berghei infection in mice induces liver injury by an IL-12- and toll-like receptor/myeloid differentiation factor 88-dependent mechanism.
    Adachi K; Tsutsui H; Kashiwamura S; Seki E; Nakano H; Takeuchi O; Takeda K; Okumura K; Van Kaer L; Okamura H; Akira S; Nakanishi K
    J Immunol; 2001 Nov; 167(10):5928-34. PubMed ID: 11698470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IFN-gamma-inducing factor/IL-18 administration mediates IFN-gamma- and IL-12-independent antitumor effects.
    Osaki T; Péron JM; Cai Q; Okamura H; Robbins PD; Kurimoto M; Lotze MT; Tahara H
    J Immunol; 1998 Feb; 160(4):1742-9. PubMed ID: 9469432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD1d-restricted natural killer T cells can down-regulate tumor immunosurveillance independent of interleukin-4 receptor-signal transducer and activator of transcription 6 or transforming growth factor-beta.
    Terabe M; Khanna C; Bose S; Melchionda F; Mendoza A; Mackall CL; Helman LJ; Berzofsky JA
    Cancer Res; 2006 Apr; 66(7):3869-75. PubMed ID: 16585215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-18 up-regulates osteoprotegerin expression in stromal/osteoblastic cells.
    Makiishi-Shimobayashi C; Tsujimura T; Iwasaki T; Yamada N; Sugihara A; Okamura H; Hayashi S; Terada N
    Biochem Biophys Res Commun; 2001 Feb; 281(2):361-6. PubMed ID: 11181055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Up-regulation of reactive oxygen species (ROS) and resistance to Fas-mediated apoptosis in the C33A cervical cancer cell line transfected with IL-18 receptor.
    Yoon- DY; Cho YS; Park JW; Kim SH; Kim JW
    Clin Chem Lab Med; 2004 May; 42(5):499-506. PubMed ID: 15202785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IFN-gamma-inducing factor up-regulates Fas ligand-mediated cytotoxic activity of murine natural killer cell clones.
    Tsutsui H; Nakanishi K; Matsui K; Higashino K; Okamura H; Miyazawa Y; Kaneda K
    J Immunol; 1996 Nov; 157(9):3967-73. PubMed ID: 8892629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.